Mark Schoenberg, the Chief Medical Officer of $URGN, sold 5,222 shares of the company on 06-08-2026 for an estimated $142,560. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.6% of their shares of this class of stock. Following this trade, they now own 139,763 shares of this class of $URGN stock.
$URGN Insider Trading Activity
$URGN insiders have traded $URGN stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $URGN stock by insiders over the last 6 months:
- MARK SCHOENBERG (Chief Medical Officer) has made 0 purchases and 4 sales selling 12,595 shares for an estimated $287,734.
- JASON DREW SMITH (General Counsel) has made 0 purchases and 3 sales selling 7,479 shares for an estimated $147,261.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$URGN Hedge Fund Activity
We have seen 78 institutional investors add shares of $URGN stock to their portfolio, and 89 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP removed 2,769,699 shares (-61.9%) from their portfolio in Q1 2026, for an estimated $49,799,188
- TORONTO DOMINION BANK added 2,616,714 shares (+inf%) to their portfolio in Q1 2026, for an estimated $47,048,517
- KYNAM CAPITAL MANAGEMENT, LP added 2,247,393 shares (+inf%) to their portfolio in Q1 2026, for an estimated $40,408,126
- OPALEYE MANAGEMENT INC. added 1,161,577 shares (+432.7%) to their portfolio in Q1 2026, for an estimated $20,885,154
- HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND removed 738,026 shares (-65.6%) from their portfolio in Q1 2026, for an estimated $13,269,707
- TANG CAPITAL MANAGEMENT LLC removed 650,000 shares (-65.0%) from their portfolio in Q4 2025, for an estimated $15,223,000
- PRICE T ROWE ASSOCIATES INC /MD/ removed 588,152 shares (-95.4%) from their portfolio in Q1 2026, for an estimated $10,574,972
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$URGN Price Targets
Multiple analysts have issued price targets for $URGN recently. We have seen 3 analysts offer price targets for $URGN in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $45.0 on 06/03/2026
- Leland Gershell from Oppenheimer set a target price of $40.0 on 05/07/2026
- Jason Kolbert from D. Boral Capital set a target price of $33.0 on 03/31/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
